News
1d
Zacks Investment Research on MSNVertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on ItVertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...
22h
Zacks.com on MSNVertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should KnowVertex Pharmaceuticals (VRTX) closed at $469.55 in the latest trading session, marking a +1.15% move from the prior day.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...
1d
Zacks Investment Research on MSNVertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for InvestorsIn the latest close session, Vertex Pharmaceuticals (VRTX) was down 1.73% at $464.20. The stock trailed the S&P 500, which registered a daily loss of 0.4%. At the same time, the Dow lost 0.98%, and ...
Discover why Vertex Pharmaceuticals outperforms amid biotech sector decline. Explore growth drivers, risks, and the ...
Vertex Pharmaceuticals Inc. closed 9.68% short of its 52-week high of $519.88, which the company reached on November 8th.
Vertex Pharmaceuticals Inc. closed 10.71% below its 52-week high of $519.88, which the company reached on November 8th.
Review quarterly and annual revenue, net income, and cash flow for Vertex Pharmaceuticals Inc (VRTX:XNAS) stock through the last fiscal year.
Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
US biotech major Vertex Pharmaceuticals (Nasdaq: VRTX) has reached a wide-ranging reimbursement deal with NHS England for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results